Experimental Medicine Study To Measure Immune Checkpoint Receptors Pd-1 And Gitr Turnover Rates In Vivo In Humans

Development of monoclonal antibodies (mAbs) targeting immune-checkpoint receptors (IMRs) for the treatment of cancer is one of the most active areas of investment in the biopharmaceutical industry. A key decision in the clinical development of anti-IMR mAbs is dose selection. Dose selection can be challenging because the traditional oncology paradigm of administering the maximum tolerated dose is not applicable to anti-IMR mAbs. Instead, dose selection should be informed by the pharmacology of immune signaling. Engaging an IMR is a key initial step to triggering pharmacologic effects, and turnover (i.e., the rate of protein synthesis) of the IMR is a key property to determining the dose level needed to engage the IMR. Here, we applied the stable isotope labeling mass spectrometry technique using C-13(6)-leucine to measure the in vivo turnover rates of IMRs in humans. The C-13(6)-leucine was administered to 10 study participants over 15 hours to measure C-13(6)-leucine enrichment kinetics in 2 IMR targets that have been clinically pursued in oncology: GITR and PD-1. We report the first measurements of GITR and PD-1 median half-lives associated with turnover to be 55.6 and >= 49.5 hours, respectively. The approach outlined here can be applied to other IMRs and, more generally, to protein targets.